Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 11;14(1):95.
doi: 10.1038/s41408-024-01076-w.

Performance of newer myeloma staging systems in a contemporary, large patient cohort

Ghulam Rehman Mohyuddin  1 , Samuel M Rubinstein  2 , Shaji Kumar  3 , S Vincent Rajkumar  3 , Rafael Fonseca  4 , Nadine H Abdallah  3 , Gregory S Calip  5 , Xiaoyan Wang  6 , Christina M Parrinello  7 , Douglas Sborov  8
Affiliations

Performance of newer myeloma staging systems in a contemporary, large patient cohort

Ghulam Rehman Mohyuddin et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare the following conflicts of interest: Mohyuddin: MashupMD: Royalties for writing, and institutional funding from Janssen for Dr. Mohyuddin being a site principal investigator for a Phase III trial. Rubinstein: Consulting with Janssen, Sanofi, Roche Diagnostics, and EUSA Pharma. Kumar: Consulting/advisory board participation (with no personal payments) with AbbVie, BMS, Janssen, Roche-Genentech, Takeda, Pfizer, Loxo Oncology, K36, Sanofi, ArcellX, and Beigene. Fonseca: Antegene: Membership on an entity’s Board of Directors or advisory committees; Regeneron: Consultancy; Oncotracker: Membership on an entity’s Board of Directors or advisory committees; Millenium: Consultancy; Binding Site: Consultancy; Janssen: Consultancy; Juno: Consultancy; Merck: Consultancy; Pfizer: Consultancy; Aztrazenica: Consultancy; Kite: Consultancy; Adaptive Biotechnologies: Membership on an entity’s Board of Directors or advisory committees; Sanofi: Consultancy; BMS (Celgene): Consultancy; Takeda: Consultancy; AMGEN: Consultancy; FISH: Patents & Royalties: FISH; AZBio: Membership on an entity’s Board of Directors or advisory committees; Bayer: Consultancy; Pharmacyclics: Consultancy; Caris Life Sciences: Membership on an entity’s Board of Directors or advisory committees; Adaptive Biotechnologies: Consultancy; AbbVie: Consultancy. Calip: Roche: Current equity holder in publicly-traded company. Wang: Flatiron Health: Current Employment; Roche: Current equity holder in publicly-traded company. Parrinello: Flatiron Health: Consultancy; Clue by Biowink: Consultancy; Evidation Health: Consultancy; EQRx: Consultancy; Roche: Current equity holder in publicly-traded company; Medicus Economics: Consultancy; Jazz Pharmaceuticals: Consultancy; Omada Health: Consultancy; Plinth: Consultancy; TTI Health: Consultancy; Canopy Care: Consultancy; IQ Solutions: Consultancy; Outcomes4Me: Consultancy. Sborov: Gilead: Research Funding; Arcellx: Consultancy, Research Funding; Bioline: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; BMS: Consultancy; Abbvie: Consultancy; Sanofi: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Amgen: Research Funding; GSK: Consultancy, Research Funding; Cantex: Research Funding; RocheX: Research Funding.

Figures

Fig. 1
Fig. 1
Kaplan-Meier product limit estimator survival functions for overall survival by MASS and R2-ISS stages.
Fig. 2
Fig. 2
Sankey plot demonstrating redistribution of patients across different R-ISS stages (R-ISS to R2-ISS on left, R-ISS to MASS on right).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9. doi: 10.1200/JCO.2015.61.2267. - DOI - PMC - PubMed
    1. Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, et al. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9:94. doi: 10.1038/s41408-019-0254-0. - DOI - PMC - PubMed
    1. Schavgoulidze A, Lauwers-Cances V, Perrot A, Cazaubiel T, Chretien ML, Moreau P, et al. Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma. Haematologica. 2023;108:1374–84. doi: 10.3324/haematol.2021.280566. - DOI - PMC - PubMed
    1. Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12:21. doi: 10.1038/s41408-022-00611-x. - DOI - PMC - PubMed
    1. D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40:3406–18. doi: 10.1200/JCO.21.02614. - DOI - PubMed